Difference between revisions of "Nilutamide (Nilandron)"
Jump to navigation
Jump to search
m |
|||
| Line 14: | Line 14: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *1996-09-19: Initial approval in combination with surgical castration for the treatment of stage D2 metastatic [[prostate cancer|carcinoma of the prostate]]. ''(Based on International Anandron Study)'' |
==Also known as== | ==Also known as== | ||
Revision as of 22:29, 4 May 2023
General information
Class/mechanism: Antiandrogen, nonsteroidal. Nilutamide competitively inhibits the effects of testosterone by interacting with the androgen receptor.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Nilutamide (Nilandron) patient drug information (Chemocare)[3]
- Nilutamide (Nilandron) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1996-09-19: Initial approval in combination with surgical castration for the treatment of stage D2 metastatic carcinoma of the prostate. (Based on International Anandron Study)
Also known as
- Brand names: Anandron, Nilandron, Zandron